{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:01:35Z","timestamp":1792519295121,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["CA278051"],"award-info":[{"award-number":["CA278051"]}]},{"name":"NIH","award":["GM119644-01"],"award-info":[{"award-number":["GM119644-01"]}]},{"DOI":"10.13039\/100017325","name":"Engineering Research Centers","doi-asserted-by":"publisher","award":["CA278051"],"award-info":[{"award-number":["CA278051"]}],"id":[{"id":"10.13039\/100017325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001395","name":"Wisconsin Alumni Research Foundation","doi-asserted-by":"publisher","award":["Wisconsin Alumni Research Foundation"],"award-info":[{"award-number":["Wisconsin Alumni Research Foundation"]}],"id":[{"id":"10.13039\/100001395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008258","name":"Hyundai Hope On Wheels","doi-asserted-by":"publisher","award":["Hyundai Hope On Wheels"],"award-info":[{"award-number":["Hyundai Hope On Wheels"]}],"id":[{"id":"10.13039\/100008258","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020317","name":"Grainger Institute for Engineering, University of Wisconsin-Madison","doi-asserted-by":"publisher","award":["Grainger Institute for Engineering, University of Wisconsin-Madison"],"award-info":[{"award-number":["Grainger Institute for Engineering, University of Wisconsin-Madison"]}],"id":[{"id":"10.13039\/100020317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00281-024-01019-4","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T13:02:27Z","timestamp":1723813347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Advances in manufacturing chimeric antigen receptor immune cell therapies"],"prefix":"10.1007","volume":"46","author":[{"given":"Apoorva","family":"Ramamurthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-0858","authenticated-orcid":false,"given":"Krishanu","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"1019_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:69","journal-title":"Blood Cancer J"},{"key":"1019_CR2","doi-asserted-by":"publisher","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","volume":"13","author":"CRF Silveira","year":"2022","unstructured":"Silveira CRF, Corveloni AC, Caruso SR, Mac\u00eado NA, Brussolo NM, Haddad F et al (2022) Cytokines as an important player in the context of CAR-T cell therapy for cancer: their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol 13:947648","journal-title":"Front Immunol"},{"key":"1019_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.21037\/atm-20-4502","volume":"8","author":"W Li","year":"2020","unstructured":"Li W, Wu L, Huang C, Liu R, Li Z, Liu L et al (2020) Challenges and strategies of clinical application of CAR-T therapy in the treatment of tumors-a narrative review. Ann Transl Med 8:1093","journal-title":"Ann Transl Med"},{"key":"1019_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41417-019-0157-z","volume":"27","author":"MM Papathanasiou","year":"2020","unstructured":"Papathanasiou MM, Stamatis C, Lakelin M, Farid S, Titchener-Hooker N, Shah N (2020) Autologous CAR T-cell therapies supply chain: challenges and opportunities? Cancer Gene Ther 27:799\u2013809","journal-title":"Cancer Gene Ther"},{"key":"1019_CR5","doi-asserted-by":"publisher","first-page":"101805","DOI":"10.1016\/j.scr.2020.101805","volume":"45","author":"E Abranches","year":"2020","unstructured":"Abranches E, Spyrou S, Ludwig T (2020) GMP Banking of Human Pluripotent Stem Cells: a US and UK perspective. Stem Cell Res 45:101805","journal-title":"Stem Cell Res"},{"key":"1019_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/bloodadvances.2022007246","volume":"7","author":"HE Stefanski","year":"2023","unstructured":"Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S et al (2023) Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv 7:541\u2013548","journal-title":"Blood Adv"},{"key":"1019_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-021-07934-1","volume":"21","author":"Z Ying","year":"2021","unstructured":"Ying Z, He T, Wang X, Zheng W, Lin N, Tu M et al (2021) Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies. BMC Cancer 21:198","journal-title":"BMC Cancer"},{"key":"1019_CR8","doi-asserted-by":"publisher","unstructured":"Rotte A, Frigault MJ, Ansari A, Gliner B, Heery C, Shah B (2022) Dose-response correlation for CAR-T cells: a systematic review of clinical studies. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2022-005678","DOI":"10.1136\/jitc-2022-005678"},{"key":"1019_CR9","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.5966\/sctm.2014-0294","volume":"4","author":"A Campbell","year":"2015","unstructured":"Campbell A, Brieva T, Raviv L, Rowley J, Niss K, Brandwein H et al (2015) Concise review: process development considerations for cell therapy. Stem Cells Transl Med 4:1155\u20131163","journal-title":"Stem Cells Transl Med"},{"key":"1019_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jcyt.2020.06.011","volume":"22","author":"M Scott","year":"2020","unstructured":"Scott M, Clarke D, Lipsitz Y, Brandwein H, Allickson J, Alzebdeh D et al (2020) Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies. Cytotherapy 22:669\u2013676","journal-title":"Cytotherapy"},{"key":"1019_CR11","unstructured":"FDA. Considerations for the development of chimeric antigen receptor (CAR) T cell products: Guidance for Industry (2024) Available: https:\/\/www.fda.gov\/media\/156896\/download"},{"key":"1019_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/cgt.2014.81","volume":"22","author":"X Wang","year":"2015","unstructured":"Wang X, Rivi\u00e8re I (2015) Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 22:85\u201394","journal-title":"Cancer Gene Ther"},{"key":"1019_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P et al (2021) Scalable Manufacturing of CAR T cells for Cancer Immunotherapy. Blood Cancer Discov 2:408\u2013422","journal-title":"Blood Cancer Discov"},{"key":"1019_CR14","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics 3:16015","journal-title":"Mol Ther Oncolytics"},{"key":"1019_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11899-019-0498-6","volume":"14","author":"S Ittershagen","year":"2019","unstructured":"Ittershagen S, Ericson S, Eldjerou L, Shojaee A, Bleickardt E, Patel M et al (2019) Industry\u2019s Giant Leap into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) immunotherapy. Curr Hematol Malig Rep 14:47\u201355","journal-title":"Curr Hematol Malig Rep"},{"key":"1019_CR16","doi-asserted-by":"publisher","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D (2023) Systematic review on CAR-T cell clinical trials up to 2022: Academic Center Input. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15041003","DOI":"10.3390\/cancers15041003"},{"key":"1019_CR17","doi-asserted-by":"publisher","first-page":"100099","DOI":"10.1016\/j.iotech.2022.100099","volume":"16","author":"DN Silva","year":"2022","unstructured":"Silva DN, Chrobok M, Ahl\u00e9n G, Blomberg P, S\u00e4llberg M, Pasetto A (2022) ATMP development and pre-GMP environment in academia: a safety net for early cell and gene therapy development and manufacturing. Immunooncol Technol 16:100099","journal-title":"Immunooncol Technol"},{"key":"1019_CR18","doi-asserted-by":"publisher","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY (2024) CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med 221. https:\/\/doi.org\/10.1084\/jem.20230903","DOI":"10.1084\/jem.20230903"},{"key":"1019_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M (2024) Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv 8:337\u2013342","journal-title":"Blood Adv"},{"key":"1019_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01981-8","author":"M Elsallab","year":"2023","unstructured":"Elsallab M, Maus MV (2023) Expanding access to CAR T cell therapies through local manufacturing. Nat Biotechnol. https:\/\/doi.org\/10.1038\/s41587-023-01981-8","journal-title":"Nat Biotechnol"},{"key":"1019_CR21","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jcyt.2019.10.005","volume":"21","author":"S Tyagarajan","year":"2019","unstructured":"Tyagarajan S, Schmitt D, Acker C, Rutjens E (2019) Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture. Cytotherapy 21:1198\u20131205","journal-title":"Cytotherapy"},{"key":"1019_CR22","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","volume":"24","author":"M Qayed","year":"2022","unstructured":"Qayed M, McGuirk JP, Myers GD, Parameswaran V, Waller EK, Holman P et al (2022) Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy 24:869\u2013878","journal-title":"Cytotherapy"},{"key":"1019_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s40883-019-00130-5","volume":"5","author":"CJ Burke","year":"2019","unstructured":"Burke CJ, Zylberberg C (2019) Sources of variability in Manufacturing of cell therapeutics. Regenerative Eng Translational Med 5:332\u2013340","journal-title":"Regenerative Eng Translational Med"},{"key":"1019_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.omtm.2022.12.004","volume":"28","author":"A Dreyzin","year":"2023","unstructured":"Dreyzin A, Panch SR, Shalabi H, Yates B, Highfill SL, Jin P et al (2023) Cryopreserved anti-CD22 and bispecific anti-CD19\/22 CAR T cells are as effective as freshly infused cells. Mol Ther Methods Clin Dev 28:51\u201361","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1019_CR25","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.ymthe.2019.05.015","volume":"27","author":"SR Panch","year":"2019","unstructured":"Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P et al (2019) Effect of cryopreservation on autologous chimeric Antigen receptor T cell characteristics. Mol Ther 27:1275\u20131285","journal-title":"Mol Ther"},{"key":"1019_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cryobiol.2018.06.007","volume":"83","author":"H Xu","year":"2018","unstructured":"Xu H, Cao W, Huang L, Xiao M, Cao Y, Zhao L et al (2018) Effects of cryopreservation on chimeric antigen receptor T cell functions. Cryobiology 83:40\u201347","journal-title":"Cryobiology"},{"key":"1019_CR27","doi-asserted-by":"publisher","first-page":"1024362","DOI":"10.3389\/fonc.2022.1024362","volume":"12","author":"K Brezinger-Dayan","year":"2022","unstructured":"Brezinger-Dayan K, Itzhaki O, Melnichenko J, Kubi A, Zeltzer L-A, Jacoby E et al (2022) Impact of cryopreservation on CAR T production and clinical response. Front Oncol 12:1024362","journal-title":"Front Oncol"},{"key":"1019_CR28","doi-asserted-by":"publisher","first-page":"592242","DOI":"10.3389\/fmed.2020.592242","volume":"7","author":"J Meneghel","year":"2020","unstructured":"Meneghel J, Kilbride P, Morris GJ (2020) Cryopreservation as a key element in the successful delivery of cell-based Therapies-A Review. Front Med 7:592242","journal-title":"Front Med"},{"key":"1019_CR29","doi-asserted-by":"publisher","first-page":"6912","DOI":"10.1182\/blood-2023-187462","volume":"142","author":"P Satwani","year":"2023","unstructured":"Satwani P, Chao K, Lopez-Garcia M, Hall M, Jin Z, Winestone LE et al (2023) Establishing costs for commercial chimeric Antigen receptor T-Cell (Tisagenlecleucel; Kymriah) in children and young adult B-Cell Acute Lymphoblastic Leukemia; a merged analysis from the Prwcc and PHIS. Blood 142:6912\u20136912","journal-title":"Blood"},{"key":"1019_CR30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jcyt.2020.03.432","volume":"22","author":"RMT Ten Ham","year":"2020","unstructured":"Ten Ham RMT, H\u00f6vels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH et al (2020) What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy 22:388\u2013397","journal-title":"Cytotherapy"},{"key":"1019_CR31","unstructured":"Tice JA, Judith ME, Walsh I, Otuonye R, Chapman V, Kumar M, Seidner DA, Ollendorf SD, Pearson MD, Whittington JD, Campbell R. Brett McQueen,Chong Kim, Mausam Patidarm Samuel McGuffin. Chimeric Antigen Receptor T-Cell Therapy for BCell Cancers: Effectiveness and Value. Available: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_CAR_T_Final_Evidence_Report_032318.pdf"},{"key":"1019_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2217\/rme-2020-0169","volume":"16","author":"J J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen J, Kefalas P (2021) The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med 16:405\u2013422","journal-title":"Regen Med"},{"key":"1019_CR33","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/bloodadvances.2022008097","volume":"7","author":"KC Potnis","year":"2023","unstructured":"Potnis KC, Di M, Isufi I, Gowda L, Seropian SE, Foss FM et al (2023) Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma. Blood Adv 7:801\u2013810","journal-title":"Blood Adv"},{"key":"1019_CR34","doi-asserted-by":"publisher","first-page":"e2245956","DOI":"10.1001\/jamanetworkopen.2022.45956","volume":"5","author":"JH Choe","year":"2022","unstructured":"Choe JH, Abdel-Azim H, Padula WV, Abou-El-Enein M (2022) Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or later therapy in relapsed or refractory diffuse large B-Cell lymphoma. JAMA Netw Open 5:e2245956","journal-title":"JAMA Netw Open"},{"key":"1019_CR35","unstructured":"National Institute for Health and Care Excellence Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. Available: https:\/\/www.nice.org.uk\/guidance\/ta894\/resources\/axicabtagene-ciloleucel-for-treating-relapsed-or-refractory-follicular-lymphoma-pdf-82613794084549"},{"key":"1019_CR36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2217\/rme-2022-0064","volume":"17","author":"E Bicudo","year":"2022","unstructured":"Bicudo E, Brass I (2022) Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of point-of-care manufacturing readiness. Regen Med 17:719\u2013737","journal-title":"Regen Med"},{"key":"1019_CR37","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y et al (2022) Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J 12:104","journal-title":"Blood Cancer J"},{"key":"1019_CR38","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","volume":"28","author":"S Agarwal","year":"2020","unstructured":"Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ (2020) In vivo generation of CAR T cells selectively in human CD4\u2009+\u2009lymphocytes. Mol Ther 28:1783\u20131794","journal-title":"Mol Ther"},{"key":"1019_CR39","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1200\/OP.22.00315","volume":"18","author":"J Mikhael","year":"2022","unstructured":"Mikhael J, Fowler J, Shah N (2022) Chimeric Antigen receptor T-Cell therapies: barriers and solutions to Access. JCO Oncol Pract 18:800\u2013807","journal-title":"JCO Oncol Pract"},{"key":"1019_CR40","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-022-01866-5","volume":"58","author":"HK Palani","year":"2023","unstructured":"Palani HK, Arunachalam AK, Yasar M, Venkatraman A, Kulkarni U, Lionel SA et al (2023) Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy\u00ae: real-world experience and cost analysis in India. Bone Marrow Transpl 58:160\u2013167","journal-title":"Bone Marrow Transpl"},{"key":"1019_CR41","doi-asserted-by":"publisher","first-page":"SP427","DOI":"10.37765\/ajmc.2023.89391","volume":"29","author":"J Tomtishen","year":"2023","unstructured":"Tomtishen J (2023) The role of automation in meeting the growing demand for CAR T-cell therapies. Am J Manag Care 29:SP427\u2013SP428","journal-title":"Am J Manag Care"},{"key":"1019_CR42","doi-asserted-by":"publisher","first-page":"1005457","DOI":"10.3389\/fimmu.2022.1005457","volume":"13","author":"N Martinez-Cibrian","year":"2022","unstructured":"Martinez-Cibrian N, Espa\u00f1ol-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V (2022) Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing. Front Immunol 13:1005457","journal-title":"Front Immunol"},{"key":"1019_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s11899-019-00522-y","volume":"14","author":"D Smith","year":"2019","unstructured":"Smith D, Heathman TRJ, Klarer A, LeBlon C, Tada Y, Hampson B (2019) Towards Automated Manufacturing for Cell therapies. Curr Hematol Malig Rep 14:278\u2013285","journal-title":"Curr Hematol Malig Rep"},{"key":"1019_CR44","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1158\/2159-8290.CD-22-1276","volume":"13","author":"MJ Dickinson","year":"2023","unstructured":"Dickinson MJ, Barba P, J\u00e4ger U, Shah NN, Blaise D, Briones J et al (2023) A novel autologous CAR-T therapy, YTB323, with preserved T-cell stemness shows enhanced CAR T-cell efficacy in preclinical and early clinical development. Cancer Discov 13:1982\u20131997","journal-title":"Cancer Discov"},{"key":"1019_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M et al (2022) Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 6:118\u2013128","journal-title":"Nat Biomed Eng"},{"key":"1019_CR46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L et al (2022) CAR T cells produced in vivo to treat cardiac injury. Science 375:91\u201396","journal-title":"Science"},{"key":"1019_CR47","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE et al (2018) Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 24:1499\u20131503","journal-title":"Nat Med"},{"key":"1019_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/mt.2011.288","volume":"20","author":"AS Bear","year":"2012","unstructured":"Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME et al (2012) Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther 20:246\u2013249","journal-title":"Mol Ther"},{"key":"1019_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.omtm.2022.11.009","volume":"28","author":"K Cornetta","year":"2023","unstructured":"Cornetta K, Lin T-Y, Pellin D, Kohn DB (2023) Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing. Mol Ther Methods Clin Dev 28:28\u201339","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1019_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ et al (2024) Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med 30:338\u2013341","journal-title":"Nat Med"},{"key":"1019_CR51","doi-asserted-by":"publisher","unstructured":"Mueller KP, Piscopo NJ, Forsberg MH, Saraspe LA, Das A, Russell B et al (2022) Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2021-004446","DOI":"10.1136\/jitc-2021-004446"},{"key":"1019_CR52","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.omtm.2023.101139","volume":"31","author":"R Kitte","year":"2023","unstructured":"Kitte R, Rabel M, Geczy R, Park S, Fricke S, Koehl U et al (2023) Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Mol Ther Methods Clin Dev 31:101139","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1019_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJC, Hamieh M, Cunanan KM et al (2017) Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature 543:113\u2013117","journal-title":"Nature"},{"key":"1019_CR54","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1002\/bit.27882","volume":"118","author":"M Sadeqi Nezhad","year":"2021","unstructured":"Sadeqi Nezhad M, Yazdanifar M, Abdollahpour-Alitappeh M, Sattari A, Seifalian A, Bagheri N (2021) Strengthening the CAR-T cell therapeutic application using CRISPR\/Cas9 technology. Biotechnol Bioeng 118:3691\u20133705","journal-title":"Biotechnol Bioeng"},{"key":"1019_CR55","doi-asserted-by":"publisher","first-page":"121409","DOI":"10.1016\/j.lfs.2023.121409","volume":"316","author":"M Naeem","year":"2023","unstructured":"Naeem M, Hazafa A, Bano N, Ali R, Farooq M, Razak SIA et al (2023) Explorations of CRISPR\/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy. Life Sci 316:121409","journal-title":"Life Sci"},{"key":"1019_CR56","doi-asserted-by":"publisher","first-page":"102010","DOI":"10.1016\/j.eclinm.2023.102010","volume":"60","author":"Y Hu","year":"2023","unstructured":"Hu Y, Zu C, Zhang M, Wei G, Li W, Fu S et al (2023) Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-hodgkin\u2019s lymphoma: a first-in-human phase I study. EClinicalMedicine 60:102010","journal-title":"EClinicalMedicine"},{"key":"1019_CR57","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097\u20132100","journal-title":"Science"},{"key":"1019_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13287-020-01741-4","volume":"11","author":"K Shankar","year":"2020","unstructured":"Shankar K, Capitini CM, Saha K (2020) Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies. Stem Cell Res Ther 11:234","journal-title":"Stem Cell Res Ther"},{"key":"1019_CR59","doi-asserted-by":"crossref","unstructured":"Klingemann H (2014) Are natural killer cells superior CAR. Drivers? Oncoimmunology. ;3: e28147","DOI":"10.4161\/onci.28147"},{"key":"1019_CR60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11684-012-0177-7","volume":"6","author":"M Cheng","year":"2012","unstructured":"Cheng M, Zhang J, Jiang W, Chen Y, Tian Z (2012) Natural killer cell lines in tumor immunotherapy. Front Med 6:56\u201366","journal-title":"Front Med"},{"key":"1019_CR61","doi-asserted-by":"publisher","first-page":"992232","DOI":"10.3389\/fimmu.2022.992232","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, Song W, Li Z, Zhang M (2022) Preclinical and clinical studies of CAR-NK-cell therapies for malignancies. Front Immunol 13:992232","journal-title":"Front Immunol"},{"key":"1019_CR62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/cmi.12580","volume":"18","author":"L Franken","year":"2016","unstructured":"Franken L, Schiwon M, Kurts C (2016) Macrophages: sentinels and regulators of the immune system. Cell Microbiol 18:475\u2013487","journal-title":"Cell Microbiol"},{"key":"1019_CR63","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958\u2013969","journal-title":"Nat Rev Immunol"},{"key":"1019_CR64","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","volume":"11","author":"EM Muntjewerff","year":"2020","unstructured":"Muntjewerff EM, Meesters LD, van den Bogaart G (2020) Antigen Cross-presentation by macrophages. Front Immunol 11:1276","journal-title":"Front Immunol"},{"key":"1019_CR65","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1002\/jcb.25895","volume":"118","author":"M Tariq","year":"2017","unstructured":"Tariq M, Zhang J, Liang G, Ding L, He Q, Yang B (2017) Macrophage Polarization: anti-cancer strategies to Target Tumor-Associated macrophage in breast Cancer. J Cell Biochem 118:2484\u20132501","journal-title":"J Cell Biochem"},{"key":"1019_CR66","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.21037\/tlcr-20-1241","volume":"10","author":"SS Sedighzadeh","year":"2021","unstructured":"Sedighzadeh SS, Khoshbin AP, Razi S, Keshavarz-Fathi M, Rezaei N (2021) A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Transl Lung Cancer Res 10:1889\u20131916","journal-title":"Transl Lung Cancer Res"},{"key":"1019_CR67","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C (2022) Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov 21:799\u2013820","journal-title":"Nat Rev Drug Discov"},{"key":"1019_CR68","doi-asserted-by":"publisher","first-page":"783305","DOI":"10.3389\/fimmu.2021.783305","volume":"12","author":"C Sloas","year":"2021","unstructured":"Sloas C, Gill S, Klichinsky M (2021) Engineered CAR-Macrophages as adoptive immunotherapies for solid tumors. Front Immunol 12:783305","journal-title":"Front Immunol"},{"key":"1019_CR69","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jlb.64.4.419","volume":"64","author":"R Andreesen","year":"1998","unstructured":"Andreesen R, Hennemann B, Krause SW (1998) Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 64:419\u2013426","journal-title":"J Leukoc Biol"},{"key":"1019_CR70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00002371-199507000-00003","volume":"18","author":"B Hennemann","year":"1995","unstructured":"Hennemann B, Scheibenbogen C, Sch\u00fcmichen C, Andreesen R (1995) Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphas Tumor Immunol 18:19\u201327","journal-title":"J Immunother Emphas Tumor Immunol"},{"key":"1019_CR71","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00002371-199709000-00005","volume":"20","author":"B Hennemann","year":"1997","unstructured":"Hennemann B, Rehm A, Kottke A, Meidenbauer N, Andreesen R (1997) Adoptive immunotherapy with tumor-cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilized peripheral blood monocytes. J Immunother 20:365\u2013371","journal-title":"J Immunother"},{"key":"1019_CR72","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M et al (2020) Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 38:947\u2013953","journal-title":"Nat Biotechnol"},{"key":"1019_CR73","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S et al (2023) Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Rep 18:585\u2013596","journal-title":"Stem Cell Rep"},{"key":"1019_CR74","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay M (2020) Macrophages enter CAR immunotherapy. Nat Methods 17(6):561","DOI":"10.1038\/s41592-020-0862-4"},{"key":"1019_CR75","doi-asserted-by":"publisher","unstructured":"Ball M, Kremp M, Qureshi R, Sonawane P, Schmierer M, VanDuzer J et al (2022) 315 characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0315","DOI":"10.1136\/jitc-2022-SITC2022.0315"},{"key":"1019_CR76","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41467-023-37872-4","volume":"14","author":"Y Chang","year":"2023","unstructured":"Chang Y, Cai X, Syahirah R, Yao Y, Xu Y, Jin G et al (2023) CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy. Nat Commun 14:2266","journal-title":"Nat Commun"},{"key":"1019_CR77","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1038\/s41467-021-22898-3","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Luo M, Dastagir SR, Nixon M, Khamhoung A, Schmidt A et al (2021) Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic. Nat Commun 12:2637","journal-title":"Nat Commun"},{"key":"1019_CR78","doi-asserted-by":"publisher","first-page":"e2000177","DOI":"10.1002\/biot.202000177","volume":"15","author":"E Costariol","year":"2020","unstructured":"Costariol E, Rotondi MC, Amini A, Hewitt CJ, Nienow AW, Heathman TRJ et al (2020) Demonstrating the manufacture of human CAR-T cells in an automated stirred-Tank Bioreactor. Biotechnol J 15:e2000177","journal-title":"Biotechnol J"},{"key":"1019_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-0716-0146-4_12","volume-title":"Chimeric Antigen Receptor T Cells: development and production","author":"J Ludwig","year":"2020","unstructured":"Ludwig J, Hirschel M (2020) Methods and process optimization for large-scale CAR T expansion using the G-Rex Cell Culture platform. In: Swiech K, Malmegrim KCR, Pican\u00e7o-Castro V (eds) Chimeric Antigen Receptor T Cells: development and production. Springer US, New York, NY, pp 165\u2013177"},{"key":"1019_CR80","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s10529-021-03076-3","volume":"43","author":"M Rotondi","year":"2021","unstructured":"Rotondi M, Grace N, Betts J, Bargh N, Costariol E, Zoro B et al (2021) Design and development of a new ambr250\u00ae bioreactor vessel for improved cell and gene therapy applications. Biotechnol Lett 43:1103\u20131116","journal-title":"Biotechnol Lett"},{"key":"1019_CR81","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-1-0716-0146-4_11","volume-title":"Chimeric Antigen Receptor T Cells: development and production","author":"TA Smith","year":"2020","unstructured":"Smith TA (2020) CAR-T cell expansion in a Xuri Cell Expansion System W25. In: Swiech K, Malmegrim KCR, Pican\u00e7o-Castro V (eds) Chimeric Antigen Receptor T Cells: development and production. Springer US, New York, NY, pp 151\u2013163"},{"key":"1019_CR82","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jcyt.2019.03.350","volume":"21","author":"A Thakkar","year":"2019","unstructured":"Thakkar A, Igarashi RY, Lee DA (2019) Automated closed-system large-scale expansion of clinical-grade natural killer cells. Cytotherapy 21:S31\u2013S32","journal-title":"Cytotherapy"},{"key":"1019_CR83","doi-asserted-by":"publisher","first-page":"913287","DOI":"10.3389\/fmed.2022.913287","volume":"9","author":"S Hort","year":"2022","unstructured":"Hort S, Herbst L, B\u00e4ckel N, Erkens F, Niessing B, Frye M et al (2022) Toward Rapid, widely available autologous CAR-T cell therapy - Artificial intelligence and automation enabling the Smart Manufacturing Hospital. Front Med 9:913287","journal-title":"Front Med"},{"key":"1019_CR84","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jcyt.2017.09.005","volume":"20","author":"F Zhu","year":"2018","unstructured":"Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B et al (2018) Closed-system manufacturing of CD19 and dual-targeted CD20\/19 chimeric antigen receptor T cells using the CliniMACS prodigy device at an academic medical center. Cytotherapy 20:394\u2013406","journal-title":"Cytotherapy"},{"key":"1019_CR85","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jcyt.2023.07.012","volume":"25","author":"N Trainor","year":"2023","unstructured":"Trainor N, Purpura KA, Middleton K, Fargo K, Hails L, Vicentini-Hogan M et al (2023) Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon platform. Cytotherapy 25:1349\u20131360","journal-title":"Cytotherapy"},{"key":"1019_CR86","doi-asserted-by":"publisher","first-page":"e10387","DOI":"10.1002\/btm2.10387","volume":"7","author":"J Ochs","year":"2022","unstructured":"Ochs J, Hanga MP, Shaw G, Duffy N, Kulik M, Tissin N et al (2022) Needle to needle robot-assisted manufacture of cell therapy products. Bioeng Transl Med 7:e10387","journal-title":"Bioeng Transl Med"},{"key":"1019_CR87","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/hum.2017.254","volume":"29","author":"U K\u00f6hl","year":"2018","unstructured":"K\u00f6hl U, Arsenieva S, Holzinger A, Abken H (2018) CAR T cells in trials: recent achievements and challenges that remain in the production of modified T cells for clinical applications. Hum Gene Ther 29:559\u2013568","journal-title":"Hum Gene Ther"},{"key":"1019_CR88","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T cell dysfunction in Cancer. Cancer Cell 33:547\u2013562","journal-title":"Cancer Cell"},{"key":"1019_CR89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","volume":"12","author":"C Aparicio","year":"2023","unstructured":"Aparicio C, Acebal C, Gonz\u00e1lez-Vallinas M (2023) Current approaches to develop off-the-shelf chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review. Exp Hematol Oncol 12:73","journal-title":"Exp Hematol Oncol"},{"key":"1019_CR90","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","volume":"55","author":"J Styczy\u0144ski","year":"2020","unstructured":"Styczy\u0144ski J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S et al (2020) Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transpl 55:126\u2013136","journal-title":"Bone Marrow Transpl"},{"key":"1019_CR91","doi-asserted-by":"publisher","unstructured":"Abdelhakim H, Abdel-Azim H, Saad A (2017) Role of \u03b1\u03b2 T cell depletion in Prevention of graft versus host disease. Biomedicines 5. https:\/\/doi.org\/10.3390\/biomedicines5030035","DOI":"10.3390\/biomedicines5030035"},{"key":"1019_CR92","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1182\/blood-2003-05-1732","volume":"102","author":"BA Kaminski","year":"2003","unstructured":"Kaminski BA, Kadereit S, Miller RE, Leahy P, Stein KR, Topa DA et al (2003) Reduced expression of NFAT-associated genes in UCB versus adult CD4\u2009+\u2009T lymphocytes during primary stimulation. Blood 102:4608\u20134617","journal-title":"Blood"},{"key":"1019_CR93","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563\u20131570","journal-title":"Cytotherapy"},{"key":"1019_CR94","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","volume":"75","author":"L Poirot","year":"2015","unstructured":"Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S et al (2015) Multiplex genome-edited T-cell Manufacturing platform for off-the-Shelf adoptive T-cell immunotherapies. Cancer Res 75:3853\u20133864","journal-title":"Cancer Res"},{"key":"1019_CR95","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","volume":"16","author":"M Themeli","year":"2015","unstructured":"Themeli M, Rivi\u00e8re I, Sadelain M (2015) New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 16:357\u2013366","journal-title":"Cell Stem Cell"},{"key":"1019_CR96","doi-asserted-by":"publisher","first-page":"9003","DOI":"10.1158\/0008-5472.CAN-09-1450","volume":"69","author":"S Okamoto","year":"2009","unstructured":"Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, Shiku H et al (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69:9003\u20139011","journal-title":"Cancer Res"},{"key":"1019_CR97","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1182\/blood-2012-01-405365","volume":"119","author":"H Torikai","year":"2012","unstructured":"Torikai H, Reik A, Liu P-Q, Zhou Y, Zhang L, Maiti S et al (2012) A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119:5697\u20135705","journal-title":"Blood"},{"key":"1019_CR98","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2021-146045","volume":"138","author":"LJ Lekakis","year":"2021","unstructured":"Lekakis LJ, Locke FL, Tees M, Neelapu SS, Malik SA, Hamadani M et al (2021) ALPHA2 study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing. Blood 138:649","journal-title":"Blood"},{"key":"1019_CR99","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","volume":"396","author":"R Benjamin","year":"2020","unstructured":"Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G et al (2020) Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396:1885\u20131894","journal-title":"Lancet"},{"key":"1019_CR100","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L (2020) Off-the-shelf allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 19:185\u2013199","journal-title":"Nat Rev Drug Discov"},{"key":"1019_CR101","doi-asserted-by":"publisher","unstructured":"Song F, Hu Y, Zhang Y, Zhang M, Yang T, Wu W et al (2023) Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2022-005701","DOI":"10.1136\/jitc-2022-005701"},{"key":"1019_CR102","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","volume":"11","author":"J Zhao","year":"2018","unstructured":"Zhao J, Lin Q, Song Y, Liu D (2018) Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 11:132","journal-title":"J Hematol Oncol"},{"key":"1019_CR103","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","volume":"30","author":"J Tipanee","year":"2022","unstructured":"Tipanee J, Samara-Kuko E, Gevaert T, Chuah MK, VandenDriessche T (2022) Universal allogeneic CAR T cells engineered with sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy. Mol Ther 30:3155\u20133175","journal-title":"Mol Ther"},{"key":"1019_CR104","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-022-30896-2","volume":"13","author":"S Jo","year":"2022","unstructured":"Jo S, Das S, Williams A, Chretien A-S, Pagliardini T, Le Roy A et al (2022) Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing. Nat Commun 13:3453","journal-title":"Nat Commun"},{"key":"1019_CR105","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S et al (2012) A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res 72:1844\u20131852","journal-title":"Cancer Res"},{"key":"1019_CR106","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho JH, Collins JJ, Wong WW (2018) Universal Chimeric Antigen Receptors for multiplexed and Logical Control of T Cell Responses. Cell 173:1426\u20131438e11","journal-title":"Cell"},{"key":"1019_CR107","doi-asserted-by":"crossref","unstructured":"Soboloff J, Kappes DJ (2017) Signaling mechanisms regulating T cell diversity and function. CRC","DOI":"10.1201\/9781315371689"},{"key":"1019_CR108","doi-asserted-by":"publisher","unstructured":"Yang Y, Kohler ME, Chien CD, Sauter CT, Jacoby E, Yan C et al (2017) TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med 9. https:\/\/doi.org\/10.1126\/scitranslmed.aag1209","DOI":"10.1126\/scitranslmed.aag1209"},{"key":"1019_CR109","doi-asserted-by":"publisher","first-page":"744823","DOI":"10.3389\/fimmu.2021.744823","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin H, Cheng J, Mu W, Zhou J, Zhu L (2021) Advances in Universal CAR-T cell therapy. Front Immunol 12:744823","journal-title":"Front Immunol"},{"key":"1019_CR110","doi-asserted-by":"publisher","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","volume":"9","author":"W Qasim","year":"2017","unstructured":"Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S et al (2017) Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 9:eaaj2013","journal-title":"Sci Transl Med"},{"key":"1019_CR111","doi-asserted-by":"publisher","unstructured":"Ca\u00ebl B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S et al (2022) Umbilical cord blood as a source of Less Differentiated T Cells to produce CD123 CAR-T cells. Cancers 14. https:\/\/doi.org\/10.3390\/cancers14133168","DOI":"10.3390\/cancers14133168"},{"key":"1019_CR112","doi-asserted-by":"crossref","unstructured":"van der Stegen SJC, Rivi\u00e8re I (2023) Unraveling barriers to iPSC-derived CAR-T cell differentiation. Cell Stem Cell. pp. 248\u2013249","DOI":"10.1016\/j.stem.2023.02.004"},{"key":"1019_CR113","doi-asserted-by":"crossref","unstructured":"Bashir Q, Shpall EJ, Champlin RE (2022) Manual of hematopoietic cell transplantation and Cellular therapies - E-Book. Elsevier Health Sciences","DOI":"10.1002\/9781119000822.hfcm071.pub2"},{"key":"1019_CR114","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/sctm.19-0389","volume":"9","author":"J Hunsberger","year":"2020","unstructured":"Hunsberger J, Simon C, Zylberberg C, Ramamoorthy P, Tubon T, Bedi R et al (2020) Improving patient outcomes with regenerative medicine: how the Regenerative Medicine Manufacturing Society plans to move the needle forward in cell manufacturing, standards, 3D bioprinting, artificial intelligence-enabled automation, education, and training. Stem Cells Transl Med 9:728\u2013733","journal-title":"Stem Cells Transl Med"},{"key":"1019_CR115","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/978-3-030-16391-4_11","volume-title":"Precision Medicine in Cancer Therapy","author":"NJ Schork","year":"2019","unstructured":"Schork NJ (2019) Artificial Intelligence and Personalized Medicine. In: Von Hoff DD, Han H (eds) Precision Medicine in Cancer Therapy. Springer International Publishing, Cham, pp 265\u2013283"},{"key":"1019_CR116","doi-asserted-by":"publisher","first-page":"e1901989","DOI":"10.1002\/adma.201901989","volume":"32","author":"O Adir","year":"2020","unstructured":"Adir O, Poley M, Chen G, Froim S, Krinsky N, Shklover J et al (2020) Integrating Artificial Intelligence and Nanotechnology for Precision Cancer Medicine. Adv Mater 32:e1901989","journal-title":"Adv Mater"},{"key":"1019_CR117","doi-asserted-by":"publisher","first-page":"176","DOI":"10.5603\/AHP.a2022.0019","volume":"53","author":"L Gil","year":"2022","unstructured":"Gil L, Grajek M (2022) Artificial intelligence and chimeric antigen receptor T-cell therapy. Acta Haematol Pol 53:176\u2013179","journal-title":"Acta Haematol Pol"},{"key":"1019_CR118","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12967-023-04292-3","volume":"21","author":"G Dagar","year":"2023","unstructured":"Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S et al (2023) Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments. J Transl Med 21:449","journal-title":"J Transl Med"},{"key":"1019_CR119","doi-asserted-by":"publisher","unstructured":"Liu L, Ma C, Zhang Z, Witkowski MT, Aifantis I, Ghassemi S et al (2022) Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse. J Immunother Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2022-005360","DOI":"10.1136\/jitc-2022-005360"},{"key":"1019_CR120","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41587-023-01687-x","volume":"41","author":"DC Kirouac","year":"2023","unstructured":"Kirouac DC, Zmurchok C, Deyati A, Sicherman J, Bond C, Zandstra PW (2023) Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat Biotechnol 41:1606\u20131617","journal-title":"Nat Biotechnol"},{"key":"1019_CR121","doi-asserted-by":"publisher","first-page":"106084","DOI":"10.1016\/j.compbiomed.2022.106084","volume":"150","author":"R Zhang","year":"2022","unstructured":"Zhang R, Han X, Lei Z, Jiang C, Gul I, Hu Q et al (2022) RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med 150:106084","journal-title":"Comput Biol Med"},{"key":"1019_CR122","doi-asserted-by":"publisher","first-page":"e0282573","DOI":"10.1371\/journal.pone.0282573","volume":"18","author":"Y Tong","year":"2023","unstructured":"Tong Y, Udupa JK, Chong E, Winchell N, Sun C, Zou Y et al (2023) Prediction of lymphoma response to CAR T cells by deep learning-based image analysis. PLoS ONE 18:e0282573","journal-title":"PLoS ONE"},{"key":"1019_CR123","doi-asserted-by":"crossref","unstructured":"Siegler EL, Kenderian SS (2020) Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Front Immunol. ;11: 1973","DOI":"10.3389\/fimmu.2020.01973"},{"key":"1019_CR124","doi-asserted-by":"publisher","first-page":"104367","DOI":"10.1016\/j.jbi.2023.104367","volume":"142","author":"A Bogatu","year":"2023","unstructured":"Bogatu A, Wysocka M, Wysocki O, Butterworth H, Pillai M, Allison J et al (2023) Meta-analysis informed machine learning: supporting cytokine storm detection during CAR-T cell therapy. J Biomed Inf 142:104367","journal-title":"J Biomed Inf"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-024-01019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-024-01019-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-024-01019-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:44:47Z","timestamp":1727365487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-024-01019-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":124,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1007\/s00281-024-01019-4","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"2 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KS receives honoraria for advisory board membership for Andson Biotech and Notch Therapeutics. No other conflicts of interest are reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"12"}}